Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | TARS1 | P26639 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29746975 | 0.91 | MME (0.47) | MMECTSCTGFBR1ACEPDCD1LG2 | |
| Trifluoroacetic Acid SCHEMBL4089038 | 0.89 | OPRM1 (0.41) | MME | |
| Trifluoroacetic Acid SCHEMBL4089079 | 0.89 | OPRM1 (0.41) | MME | |
| SCHEMBL29449289 | 0.88 | MME (0.50) | MMECTSCTGFBR1ACEPDCD1LG2 | |
| SCHEMBL29375393 | 0.88 | MME (0.50) | MMECTSCTGFBR1ACEPDCD1LG2 | |
| SCHEMBL4092941 | 0.84 | MME (0.39) | MMECTSCTGFBR1ACEPDCD1LG2 | |
| SCHEMBL30011153 | 0.84 | MME (0.42) | MMECTSCTGFBR1PDCD1LG2CD274 | |
| SCHEMBL30906339 | 0.83 | MME (0.41) | MMECTSCTGFBR1PDCD1LG2CD274 | |
| Trifluoroacetic Acid SCHEMBL16496793 | 0.82 | OPRD1 (0.35) | MME | |
| SCHEMBL29564528 | 0.82 | ACE (0.54) | MMECTSCTGFBR1ACEPDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | MME 965/4885CTSC 619/4885TGFBR1 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.